Category

News

PamGene highlights new publications underscoring the importance of its kinome activity profiling technology, the basis of the IOpener® diagnostic test

Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlights eight publications in international journals that have confirmed that kinase-activity...
Read More

PamGene, Novigenix and Radboud University Medical Center secure Eurostars funding to develop a multi-omic predictive immunotherapy response test for bladder cancer patients

PRECISE, a Dutch-Swiss consortium between PamGene International B.V., Novigenix SA and Radboud University Medical Center, has been awarded a Eurostars grant of up to €1 million to develop a novel...
Read More

Learning why patients display poor response to a therapy by looking at deregulated kinase signaling

Kinases have been running like a thread through Dr. Julhash Uddin Kazi’s career. They also played the lead part in the Lund University’s Associate Professor of Molecular Medicine’s recent Nature...
Read More

PamGene receives extended ISO 13485:2016 certification for its IOpener® immunotherapy selection test services

PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, today announced it has received extension of its ISO 13485:2016 certification. The...
Read More

PamGene shares experience on biomarker development and ICI therapy response prediction at Cancer Bioinformatics Symposium

The 1st Annual Cancer Bioinformatics Symposium at the University of Toledo College of Medicine and Life Sciences will take place February 5th. The full day, online event champions collaboration between...
Read More

Journal for ImmunoTherapy of Cancer publication – Kinase activity profiling as a predictor of response to ICI treatment

Journal for ImmunoTherapy of Cancer published the results of a study focusing on the potential of kinase activity profiling to predict the response of Melanoma and Non Small Cell Lung...
Read More

“Kinases and cell behavior are the basis of my work”

“I’m focused on continuous improvement of therapeutic strategies and to translate these into solutions for patients suffering from lung diseases,” tells Dr. Astrid Weiß, post doc. at the Biomedical Research...
Read More

University Toledo turns supercomputers toward cancer research

“When you combine traditional laboratory techniques with advanced computational biology techniques, you can significantly improve the quality and quantity of your research and produce experimental results that give you much...
Read More

Clinical benefit from immune checkpoint inhibition in advanced melanoma and NSCLC can be predicted by tyrosine kinase activity profiling

Blood-based biomarker test has the potential to decrease the number of both over- and undertreated patients improving overall response rate, reduce unnecessary side effects and help saving costs. PamGene, a...
Read More

PamGene announces presentation of positive interim results for its blood-based biomarker test to predict clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC at the 2020 European Society for Medical Oncology ESMO

PamGene, a biotech and services company focused on the development and commercialization of multiple novel biomarker panels for patient stratification in immuno-oncology, is pleased to announce that new data from...
Read More
1 2 3 4